Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01060579 · ClinicalTrials.gov registry record · Phase 2
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
NCT01060579 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 217 participants.
The verdict
NCT01060579, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
Study Summary
A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost. Hypothesis: The ocular hypotensive efficacy of each dose of AR-12286 ophthalmic solution will not be different from that of an active control.
Interventions
- DRUG Latanoprost ophthalmic solution
- DRUG AR-12286 0.5% ophthalmic solution
- DRUG AR-12286 0.25% Ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01060579
The ClinicalTrials.gov registry entry for NCT01060579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Latanoprost ophthalmic solution is the first listed.
NCT01060579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01060579 about?
NCT01060579 is a clinical study titled "Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure". A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost. Hypothesis: The ocular hypotensive efficacy of each dose of AR-12286 ophthalmic solution will not be different from that of an active c...
What is the current status of trial NCT01060579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2010-02. Estimated completion is 2010-08.
What interventions are being tested in trial NCT01060579?
The interventions under investigation include: Latanoprost ophthalmic solution (DRUG), AR-12286 0.5% ophthalmic solution (DRUG), AR-12286 0.25% Ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT01060579?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.